-
61
An Analysis for IDH‐Mutant Grade 4 Astrocytoma Based on WHO CNS 5: Implication of Clinical Practice
Published 2025-07-01“…Eleven patients received adjuvant tumor‐treating fields (TTFields). Results The median follow‐up was 15.7 months. …”
Get full text
Article -
62
Soil suction dataset from a lime & cement treated embankment, from 2010 to 2023
Published 2025-06-01“…Other sensors recorded the volumetric water content only, in the core of the embankment, its base and the platform [3]. All data are available from 2010 to 2023. A weather station recorded precise meteorological data from 2010 to 2013.The goal of this real size embankment was to evaluate the sustainability of treated soils used in earth structures and to test the re-use of very plastic clay thanks to adapted soil treatment. …”
Get full text
Article -
63
-
64
Preventive strategies and factors associated with surgically treated necrotising enterocolitis in extremely preterm infants: an international unit survey linked with retrospective cohort data analysis
Published 2019-10-01“…Objectives To compare necrotising enterocolitis (NEC) prevention practices and NEC associated factors between units from eight countries of the International Network for Evaluation of Outcomes of Neonates, and to assess their association with surgical NEC rates.Design Prospective unit-level survey combined with retrospective cohort study.Setting Neonatal intensive care units in Australia/New Zealand, Canada, Finland, Israel, Spain, Sweden, Switzerland and Tuscany (Italy).Patients Extremely preterm infants born between 240 to 286 weeks’ gestation, with birth weights<1500 g, and admitted between 2014–2015.Exposures NEC prevention practices (probiotics, feeding, donor milk) using responses of an on-line pre-piloted questionnaire containing 10 questions and factors associated with NEC in literature (antenatal steroids, c-section, indomethacin treated patent ductus arteriosus and sepsis) using cohort data.Outcome measures Surgical NEC rates and death following NEC using cohort data.Results The survey response rate was 91% (153 units). …”
Get full text
Article -
65
-
66
Quality of life of treated opiate addicts in the methadone maintenance program and those treated with buprenorphine
Published 2017-01-01“…The aim of this study was to determine which addicts characteristics, as well as the characteristics of the addiction and treatment have predicative influence on the quality of life of the opiate addicts treated in the methadone maintenance program and those treated with buprenorphine. …”
Get full text
Article -
67
Acute Myeloid Leukemia: To Treat or Not to Treat – Experience from a Resource-limited Setting
Published 2025-01-01“…MATERIALS AND METHODS: A 5-year retrospective study was conducted in two tertiary healthcare facilities in Nigeria. Data were retrieved from the case files of patients diagnosed with AML from July 2016 to June 2021. …”
Get full text
Article -
68
Treating rheumatoid arthritis to target: Revision of the 2014 International Expert Group Recommendations
Published 2016-09-01“…The revised recommendations consider the results of numerous randomized controlled and cohort studies, as well as the data of an extensive systematic review of the literature. …”
Get full text
Article -
69
-
70
Prognostic Value of KRAS/TP53 Status for Overall Survival in First-Line Monoimmunotherapy and Chemoimmunotherapy Treated Patients With Nonsquamous NSCLC in the Netherlands: A Brief...
Published 2024-12-01“…In a separate analysis of treatment subgroups, mutated TP53 was associated with longer median OS in chemoimmunotherapy treated KRAS-wildtype patients (468 versus 341 d, HR = 0.71, p = 0.029) but not in monoimmunotherapy treated patients with KRAS-wildtype (512 versus 371 d, HR = 0.91, p = 0.78). …”
Get full text
Article -
71
Descriptive analysis of durvalumab use in unresectable stage III non-small cell lung cancer in patients treated in Quebec’s University teaching hospitals
Published 2024-12-01“…Median PFS was 40 months in patients treated with CRT + durvalumab vs 6.9 months with CRT alone, with a hazard ratio (HR) of 0.22 (95% confidence interval (CI) 0.13-0.37; p < 0.0001). …”
Get full text
Article -
72
-
73
Real-World-Data of Treatment-Naïve and Previously Treated Patients Receiving Up to 3 Injections of Faricimab in Neovascular Age-Related Macular Degeneration
Published 2024-12-01“…Demographic data, treatment history, best corrected visual acuity (BCVA), anatomic parameters, and adverse events (AEs) were collected.Results: After one IVI of faricimab, previously treated (n=160) eyes with a mean of 33.51 IVIs and treatment-naïve (n=10) eyes showed a mean BCVA gain of +0.59± 0.52 letters (p=0.364) and +5.00± 6.50 letters (p=0.461), respectively, and a mean central subfield thickness (CST) reduction of − 27.65± 5.33 μm (p< 0.001) and − 94.10± 39.74 μm (p=0.042), respectively. …”
Get full text
Article -
74
Using chemotherapy against metastatic pancreatic neuroendocrine neoplasm: how aggressively do we treat it? Real world data from a Brazilian Cancer Center
Published 2022-10-01“…Conclusion: Our real world data shows that doublet platin is a preferred and active schema for treating pNEN, especially in first and second line. …”
Get full text
Article -
75
Coverage and contextual factors associated with insecticide-treated net use among women of reproductive age in Nigeria: evidence from the 2021 malaria indicator survey data.
Published 2025-01-01“…We conducted a secondary data analysis of the 2021 Malaria Indicator Survey (NMIS). …”
Get full text
Article -
76
-
77
Evaluation of Healthcare Outcomes of Patients Treated with 3D-Printed-Titanium and PEEK Cages During Fusion Procedures in the Lumbar Spine
Published 2025-01-01“…Katherine A Corso,1 Andreas A Teferra,1 Annalisa Michielli,2 Kristin Corrado,2 Amy Marcini,3 Mark Lotito,2 Caroline Smith,4 Michelle Costa,4 Jill Ruppenkamp,1 Anna Wallace1 1MedTech Epidemiology and Real-World Data Science, Johnson & Johnson, Raynham, Massachusetts & New Brunswick, New Jersey, USA; 2Clinical Research, DePuy Synthes, MedTech, Johnson & Johnson, Raynham, Massachusetts, USA; 3Medical Affairs, DePuy Synthes, MedTech, Johnson & Johnson, Raynham, Massachusetts, USA; 4Franchise HEMA, DePuy Synthes, Medtech, Johnson & Johnson, Raynham, Massachusetts, USACorrespondence: Katherine A Corso, MedTech Epidemiology and Real-world Data Science, Johnson & Johnson, 325 Paramount Drive, Raynham, MA, 02767, USA, Tel +1 857-523-0279, Email kcorso1@its.jnj.comPurpose: The objective of this observational, real-world study was to describe reoperation, revision, index healthcare utilization and hospital costs among patients treated with PEEK (polyetheretherketone) or 3D-printed-titanium cages during lumbar/lumbosacral posterior fusion procedures, either TLIF (transforaminal lumbar interbody fusion) or PLIF (posterior lumbar interbody fusion). …”
Get full text
Article -
78
-
79
Treating osteoarthrosis in terms of the safety of pharmacotherapy
Published 2009-03-01Get full text
Article -
80